Assess Incidence and Prevalence of Brain Metastasis and Its impact on Clinical Outcomes among Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-small Cell Lung Cancer Patients Receiving ALK Inhibitors as First-Line Treatment in the United States (ALK+ mNSCLC)

ENCePP Code of conduct

No information provided.

Data sources

No information provided.

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  Yes
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  Not applicable

Procedures

No information provided.